Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 2:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 84 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Mild-to-moderate Alzheimer's Disease Patients Clear all
Completed Phase 3 Interventional Results available

Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil

NCT01955161
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Placebo, Idalopirdine
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
50 Years and older
Enrollment
933 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
46
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 40 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2017 · Synced Oct 7, 2026, 2:05 AM EDT
Completed Phase 2 Interventional

A Phase II, Multicenter, Double Blind, Placebo-Controlled Safety, Tolerability Study of BMS-708163 in Patients With Mild to Moderate Alzheimer's Disease

NCT00810147
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
BMS-708163, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
50 Years to 90 Years
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
35
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Oct 7, 2026, 2:05 AM EDT
Completed Phase 2 Interventional Results available

A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab

NCT01723826
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Crenezumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
47
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2020 · Synced Oct 7, 2026, 2:05 AM EDT
Completed Phase 2 Interventional

Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil

NCT01266525
View directory record Official record
Conditions
Dementia Alzheimer's Type
Interventions
SAR110894, placebo (for SAR110894), Donepezil
Drug
Lead sponsor
Sanofi
Industry
Eligibility
55 Years and older
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
27
States / cities
Gilbert, Arizona • Phoenix, Arizona • Costa Mesa, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Oct 7, 2026, 2:05 AM EDT
Terminated Phase 2 Interventional

AAB-001 (Bapineuzumab) Open-Label, Long-Term Extension Study in Patients With Mild to Moderate Alzheimer's Disease

NCT00606476
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Bapineuzumab (AAB-001)
Drug
Lead sponsor
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Industry
Eligibility
Not listed
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
29
States / cities
Peoria, Arizona • Sun City, Arizona • Encino, California + 26 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2013 · Synced Oct 7, 2026, 2:05 AM EDT
Completed Phase 2 Interventional Results available

Study of BHV-4157 in Alzheimer's Disease

NCT03605667
View directory record Official record
Conditions
Alzheimer Disease
Interventions
troriluzole, Placebo oral capsule
Drug
Lead sponsor
Biohaven Pharmaceuticals, Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
44
States / cities
Phoenix, Arizona • Sun City, Arizona • Fullerton, California + 39 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2023 · Synced Oct 7, 2026, 2:05 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)

NCT02614131
View directory record Official record
Conditions
Healthy, Alzheimer's Disease, Mild Cognitive Impairment
Interventions
LY2599666, Solanezumab, Placebo SC, Placebo IV
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
20 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
3
States / cities
Glendale, California • Marlton, New Jersey • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 17, 2020 · Synced Oct 7, 2026, 2:05 AM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease

NCT01561053
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Albumin 5%, Albumin 20%, Immunoglobulin
Biological
Lead sponsor
Instituto Grifols, S.A.
Industry
Eligibility
55 Years to 85 Years
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
22
States / cities
Sacramento, California • Denver, Colorado • Washington D.C., District of Columbia + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Oct 7, 2026, 2:05 AM EDT
Completed Phase 1 Interventional

Multiple Dose Safety Study of NPT088 in Patients With Mild to Moderate Probable Alzheimer's Disease

NCT03008161
View directory record Official record
Conditions
Alzheimer Disease
Interventions
NPT088, Placebo
Drug
Lead sponsor
Proclara Biosciences, Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
23
States / cities
Costa Mesa, California • Fullerton, California • Long Beach, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2019 · Synced Oct 7, 2026, 2:05 AM EDT
Completed Phase 3 Interventional

Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier)

NCT00575055
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Bapineuzumab 0.5 mg/kg, Placebo Control, Bapineuzumab 1.0 m/kg
Drug
Lead sponsor
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Industry
Eligibility
50 Years to 88 Years
Enrollment
1,121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
186
States / cities
Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 143 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2013 · Synced Oct 7, 2026, 2:05 AM EDT
Not listed Phase 3 Interventional

Evaluation of 3APS in Patients With Mild to Moderate Alzheimer's Disease

NCT00088673
View directory record Official record
Conditions
Alzheimer Disease
Interventions
3APS
Drug
Lead sponsor
Bellus Health Inc. - a GSK company
Industry
Eligibility
50 Years and older
Enrollment
950 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
50
States / cities
Peoria, Arizona • Phoenix, Arizona • Hot Springs, Arkansas + 40 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2007 · Synced Oct 7, 2026, 2:05 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease

NCT00838110
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Dimebon, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
742 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
93
States / cities
Mobile, Alabama • Northport, Alabama • Little Rock, Arkansas + 82 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2018 · Synced Oct 7, 2026, 2:05 AM EDT
Completed Phase 2 Interventional Results available

ELND005 in Patients With Mild to Moderate Alzheimer's Disease

NCT00568776
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Placebo Control, ELND005
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
50
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2019 · Synced Oct 7, 2026, 2:05 AM EDT
Not listed Phase 2 Interventional

Safety Study of Passive Immunization for Patients With Mild to Moderate Alzheimer's Disease

NCT00174525
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
AAB-001
Drug
Lead sponsor
Pharmacology Research Institute
Other
Eligibility
50 Years to 85 Years
Timeline
2005 – 2008
U.S. locations
2
States / cities
Los Alamitos, California • Northridge, California
Source: ClinicalTrials.gov public record
Updated May 9, 2012 · Synced Oct 7, 2026, 2:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of RO7105705 in Healthy Participants and Participants With Mild-to-Moderate Alzheimer's Disease

NCT02820896
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Placebo, RO7105705
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 7, 2026, 2:05 AM EDT
Completed Phase 2 Interventional Results available

Efficacy of Circadin® 2 mg in Patients With Mild to Moderate Alzheimer Disease Treated With AChE Inhibitor

NCT00940589
View directory record Official record
Conditions
Alzheimer's Disease, Sleep Disorder
Interventions
Circadin, Placebo
Drug
Lead sponsor
Neurim Pharmaceuticals Ltd.
Industry
Eligibility
50 Years to 85 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
4
States / cities
Brooksville, Florida • St. Petersburg, Florida • Mount Arlington, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2018 · Synced Oct 7, 2026, 2:05 AM EDT
Completed Phase 2 Interventional Results available

Study of Octagam (Intravenous Immunoglobulin [IVIG]) 10% on the Treatment of Mild to Moderate Alzheimer's Disease

NCT00812565
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Placebo, octagam 10%
Drug · Biological
Lead sponsor
Octapharma
Industry
Eligibility
50 Years to 85 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Hoboken, New Jersey
Source: ClinicalTrials.gov public record
Updated May 5, 2014 · Synced Oct 7, 2026, 2:05 AM EDT
Completed Phase 2 Interventional Results available

Safety and Effectiveness Study of Intranasal Insulin Glulisine on Cognitive and Memory in Mild-Mod AD Patients.

NCT01436045
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Insulin glulisine, Saline
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
65 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 19, 2015 · Synced Oct 7, 2026, 2:05 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease

NCT06125951
View directory record Official record
Conditions
Dementia Moderate, Dementia, Mild, Alzheimer Disease
Interventions
Xanamem, Placebo
Drug
Lead sponsor
Actinogen Medical
Industry
Eligibility
50 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
19
States / cities
Carlsbad, California • Sherman Oaks, California • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 7, 2026, 2:05 AM EDT
Completed Phase 2 Interventional

Testing the Safety and Preliminary Efficacy of the New Drug ORY-2001 in Mild to Moderate Alzheimer's Disease

NCT03867253
View directory record Official record
Conditions
Mild to Moderate Alzheimer's Disease
Interventions
ORY-2001 Low dose, ORY-2001 High dose, Placebo
Drug
Lead sponsor
Oryzon Genomics S.A.
Industry
Eligibility
50 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Wellington, Florida • Columbus, Georgia • Princeton, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2021 · Synced Oct 7, 2026, 2:05 AM EDT
Not listed Phase 3 Interventional

Open-Label Extension of the Phase III Study With Tramiprosate (3APS) in Patients With Mild to Moderate Alzheimer's Disease

NCT00314912
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Tramiprosate (3APS)
Drug
Lead sponsor
Bellus Health Inc. - a GSK company
Industry
Eligibility
50 Years and older
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2007 · Synced Oct 7, 2026, 2:05 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease

NCT04639050
View directory record Official record
Conditions
Alzheimers Disease
Interventions
RO7126209, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 85 Years
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
15
States / cities
Atlantis, Florida • Clermont, Florida • Lady Lake, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 7, 2026, 2:05 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil

NCT00829374
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Dimebon, Placebo comparator
Drug
Lead sponsor
Medivation, Inc.
Industry
Eligibility
50 Years and older
Enrollment
1,003 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
52
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2016 · Synced Oct 7, 2026, 2:05 AM EDT
Terminated Phase 2 Interventional Results available

Open-Label Extension of the PTI-125-04 Study in Mild-to-Moderate Alzheimer's Disease

NCT05352763
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
simufilam
Drug
Lead sponsor
Cassava Sciences, Inc.
Industry
Eligibility
50 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
9
States / cities
Gilbert, Arizona • Imperial, California • Delray Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2025 · Synced Oct 7, 2026, 2:05 AM EDT